Context Therapeutics (NASDAQ: CNTX) net income
Context Therapeutics reported a net loss of $36.1m for fiscal 2025; in fiscal 2024 it reported a net loss of $26.7m. Earnings per share were −$0.38.
Context Therapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 5 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$36.1m | — | — | −$0.38 |
| 2024 | −$26.7m | — | — | −$0.46 |
| 2023 | −$24.0m | — | — | −$1.50 |
| 2022 | −$14.8m | — | — | −$0.93 |
| 2021 | −$10.5m | −257.4% | — | −$3.69 |
| 2020 | $6.6m | — | — | $3.07 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Context Therapeutics net income compared with its sector
By net income for its latest fiscal year, Context Therapeutics ranks 231st of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 229th | Hyperfine | −$35.6m | −262.3% |
| 230th | Canton Strategic | −$35.9m | — |
| 231st | Context Therapeutics | −$36.1m | — |
| 232nd | AngioDynamics | −$36.7m | −11.5% |
| 233rd | Sanara Medtech | −$37.6m | −36.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Context Therapeutics
- How much did Context Therapeutics earn in fiscal 2025?
- Context Therapeutics reported a net loss of $36.1m for fiscal 2025. In fiscal 2024 it reported a net loss of $26.7m.
- What are the earnings per share of Context Therapeutics?
- They were −$0.38 in fiscal 2025, compared with −$0.46 in fiscal 2024.
- What was the most profitable year for Context Therapeutics?
- Of its last 6 fiscal years, fiscal 2020, with $6.6m.
- Where does Context Therapeutics rank in its sector by net income?
- It ranks 231st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Context Therapeutics come from?
- From the annual report (Form 10-K) that Context Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Context Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Context Therapeutics: the Context Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.